Istvan Gyertyan
Overview
Explore the profile of Istvan Gyertyan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
852
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tajti B, Yoon O, Ernyey A, Gaspar A, Varga B, Gyertyan I
Biomed Res Int
. 2023 Dec;
2023:6625491.
PMID: 38149091
The Barnes maze, a well-known spatial-learning paradigm, is based on the innate fear of rodents of large open spaces and their drive to hide. However, additional aversive stimuli (strong light...
2.
Ernyey A, Kassai F, Kozma K, Plangar I, Somfai Z, Miklya I, et al.
Geroscience
. 2023 Jun;
46(1):417-429.
PMID: 37306892
Aging-associated cognitive disorders lack proper medication. To meet this need translation-wise, modification of the animal models is also required. In the present study, effect of the putative anti-aging compound (2R)-1-(1-benzofuran-2-yl)-N-propylpentane-2-amine...
3.
Gaspar A, Hutka B, Ernyey A, Tajti B, Varga B, Zadori Z, et al.
Front Pharmacol
. 2023 Jan;
13:1122260.
PMID: 36686687
[This corrects the article DOI: 10.3389/fphar.2021.662173.].
4.
Gaspar A, Hutka B, Ernyey A, Tajti B, Varga B, Zadori Z, et al.
Sci Rep
. 2022 Nov;
12(1):20247.
PMID: 36424423
The intracerebroventricularly (icv) injected streptozotocin (STZ) induced brain state is a widely used model of sporadic Alzheimer-disease (AD). However, data have been generated in young, naive albino rats. We postulate...
5.
Varga B, Gaspar A, Ernyey A, Hutka B, Tajti B, Zadori Z, et al.
Physiol Int
. 2022 Sep;
PMID: 36057105
Our aim was to establish a pharmacologically induced neurovascular uncoupling (NVU) method in rats as a model of human cognitive decline. Pharmacologically induced NVU with subsequent neurological and cognitive defects...
6.
Kassai F, Ernyey A, Kozma K, Plangar I, Gyertyan I
J Integr Neurosci
. 2022 Feb;
21(1):12.
PMID: 35164448
: In the framework of a larger project aiming to test putative cognitive enhancer drugs in a system with improved translational validity, we established a rodent test battery, where different,...
7.
Gyertyan I, Lubec J, Ernyey A, Gerner C, Kassai F, Kalaba P, et al.
Sci Rep
. 2021 Dec;
11(1):23962.
PMID: 34907284
The lack of novel cognitive enhancer drugs in the clinic highlights the prediction problems of animal assays. The objective of the current study was to test a putative cognitive enhancer...
8.
Gaspar A, Hutka B, Ernyey A, Tajti B, Varga B, Zadori Z, et al.
Front Pharmacol
. 2021 May;
12:662173.
PMID: 34025423
Intracerebroventricularly injected streptozotocin (STZ)-induced learning impairment has been an increasingly used rat model of Alzheimer disease. The evoked pathological changes involve many symptoms of the human disease (cognitive decline, increase...
9.
Gyertyan I, Kassai F, Kozma K, Kitka T, Ernyey A
Brain Res Bull
. 2020 Oct;
165:238-245.
PMID: 33086133
Introduction: The serial clinical failures of novel cognitive enhancer candidates point out the lack of predictive power in the preceding animal experimentation. For a more predictive profiling of putative procognitive...
10.
Gyertyan I
Expert Opin Drug Discov
. 2020 Mar;
15(6):659-670.
PMID: 32183541
Introduction: Disorders of the brain pose the biggest health challenge of this century with new and highly efficacious medications urgently needed. This article discusses the challenges of meeting this increasing...